Durvalumab Results Spark Hope for Progress in Advanced NSCLC

Christin L. Melton, ELS
Published: Tuesday, Apr 16, 2019
Mark A. Socinski, MD
Mark A. Socinski, MD
After a signiciant drought in progress in treating stage III non–small cell lung cancer (NSCLC), the thoracic oncology community is decidedly excited by the recently published results of the phase III PACIFIC trial (NCT02125461).1 The PACIFIC investigators found that administering the immune checkpoint inhibitor (ICI) durvalumab (Imfinzi) to patients with stage III unresectable NSCLC after concurrent chemoradiotherapy (CCRT) significantly enhanced overall survival (OS) with an acceptable increase in toxicity.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Community Practice Connections™: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for NursesJun 29, 20191.5
Publication Bottom Border
Border Publication
x